Neal I Lindeman1, Philip T Cagle2, Dara L Aisner3, Maria E Arcila4, Mary Beth Beasley5, Eric H Bernicker6, Carol Colasacco7, Sanja Dacic8, Fred R Hirsch9, Keith Kerr10, David J Kwiatkowski11, Marc Ladanyi12, Jan A Nowak13, Lynette Sholl14, Robyn Temple-Smolkin15, Benjamin Solomon16, Lesley H Souter, Erik Thunnissen17, Ming S Tsao18, Christina B Ventura7, Murry W Wynes19, Yasushi Yatabe20. 1. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: nlindeman@partners.org. 2. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas. 3. Department of Pathology, University of Colorado School of Medicine, Denver, Colorado. 4. Diagnostic and Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Pathology & Medicine, Pulmonary, Critical Care and Sleep Medicine, New York, New York. 6. Cancer Research Program, Houston Methodist Research Institute, Houston, Texas. 7. Pathology and Laboratory Quality Center, College of American Pathologists, Northfield, Illinois. 8. Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania. 9. Department of Medicine and Pathology, University of Colorado, Denver, Colorado. 10. Department of Pathology, University of Aberdeen, Aberdeen, Scotland. 11. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 12. Molecular Diagnostics Service, Memorial Sloan Kettering Cancer Center, New York, New York. 13. Department of Molecular Pathology, Roswell Park Cancer Institute, Buffalo, New York. 14. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. 15. Clinical and Scientific Affairs Division, Association for Molecular Pathology, Bethesda, Maryland. 16. Molecular Therapeutics and Biomarkers Laboratory, Peter Maccallum Cancer Center, Melbourne, Australia. 17. Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. 18. Department of Laboratory Medicine and Pathobiology, Princess Margaret Cancer Center, Toronto, Ontario, Canada. 19. Scientific Affairs, International Association for the Study of Lung Cancer, Aurora, Colorado. 20. Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
Abstract
CONTEXT: In 2013, an evidence-based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology to set standards for the molecular analysis of lung cancers to guide treatment decisions with targeted inhibitors. New evidence has prompted an evaluation of additional laboratory technologies, targetable genes, patient populations, and tumor types for testing. OBJECTIVE: To systematically review and update the 2013 guideline to affirm its validity; to assess the evidence of new genetic discoveries, technologies, and therapies; and to issue an evidence-based update. DESIGN: The College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology convened an expert panel to develop an evidence-based guideline to help define the key questions and literature search terms, review abstracts and full articles, and draft recommendations. RESULTS: Eighteen new recommendations were drafted. The panel also updated 3 recommendations from the 2013 guideline. CONCLUSIONS: The 2013 guideline was largely reaffirmed with updated recommendations to allow testing of cytology samples, require improved assay sensitivity, and recommend against the use of immunohistochemistry for EGFR testing. Key new recommendations include ROS1 testing for all adenocarcinoma patients; the inclusion of additional genes (ERBB2, MET, BRAF, KRAS, and RET) for laboratories that perform next-generation sequencing panels; immunohistochemistry as an alternative to fluorescence in situ hybridization for ALK and/or ROS1 testing; use of 5% sensitivity assays for EGFR T790M mutations in patients with secondary resistance to EGFR inhibitors; and the use of cell-free DNA to "rule in" targetable mutations when tissue is limited or hard to obtain.
CONTEXT: In 2013, an evidence-based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology to set standards for the molecular analysis of lung cancers to guide treatment decisions with targeted inhibitors. New evidence has prompted an evaluation of additional laboratory technologies, targetable genes, patient populations, and tumor types for testing. OBJECTIVE: To systematically review and update the 2013 guideline to affirm its validity; to assess the evidence of new genetic discoveries, technologies, and therapies; and to issue an evidence-based update. DESIGN: The College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology convened an expert panel to develop an evidence-based guideline to help define the key questions and literature search terms, review abstracts and full articles, and draft recommendations. RESULTS: Eighteen new recommendations were drafted. The panel also updated 3 recommendations from the 2013 guideline. CONCLUSIONS: The 2013 guideline was largely reaffirmed with updated recommendations to allow testing of cytology samples, require improved assay sensitivity, and recommend against the use of immunohistochemistry for EGFR testing. Key new recommendations include ROS1 testing for all adenocarcinomapatients; the inclusion of additional genes (ERBB2, MET, BRAF, KRAS, and RET) for laboratories that perform next-generation sequencing panels; immunohistochemistry as an alternative to fluorescence in situ hybridization for ALK and/or ROS1 testing; use of 5% sensitivity assays for EGFRT790M mutations in patients with secondary resistance to EGFR inhibitors; and the use of cell-free DNA to "rule in" targetable mutations when tissue is limited or hard to obtain.
Authors: Michael Allgäuer; Jan Budczies; Petros Christopoulos; Volker Endris; Amelie Lier; Eugen Rempel; Anna-Lena Volckmar; Martina Kirchner; Moritz von Winterfeld; Jonas Leichsenring; Olaf Neumann; Stefan Fröhling; Roland Penzel; Michael Thomas; Peter Schirmacher; Albrecht Stenzinger Journal: Transl Lung Cancer Res Date: 2018-12
Authors: Petros Christopoulos; Martina Kirchner; Volker Endris; Albrecht Stenzinger; Michael Thomas Journal: J Thorac Dis Date: 2018-06 Impact factor: 2.895
Authors: Elliot B Levy; Maria I Fiel; Stanley R Hamilton; David E Kleiner; Shannon J McCall; Peter Schirmacher; William Travis; Michael D Kuo; Robert D Suh; Alda L Tam; Shaheen U Islam; Katherine Ferry-Galow; Rebecca A Enos; James H Doroshow; Hala R Makhlouf Journal: J Clin Oncol Date: 2020-03-05 Impact factor: 44.544
Authors: Wafik S El-Deiry; Richard M Goldberg; Heinz-Josef Lenz; Anthony F Shields; Geoffrey T Gibney; Antoinette R Tan; Jubilee Brown; Burton Eisenberg; Elisabeth I Heath; Surasak Phuphanich; Edward Kim; Andrew J Brenner; John L Marshall Journal: CA Cancer J Clin Date: 2019-05-22 Impact factor: 508.702
Authors: D G Bebb; J Agulnik; R Albadine; S Banerji; G Bigras; C Butts; C Couture; J C Cutz; P Desmeules; D N Ionescu; N B Leighl; B Melosky; W Morzycki; F Rashid-Kolvear; Clin Lab; H S Sekhon; A C Smith; T L Stockley; E Torlakovic; Z Xu; M S Tsao Journal: Curr Oncol Date: 2019-08-01 Impact factor: 3.677
Authors: Alexander Drilon; Salvatore Siena; Rafal Dziadziuszko; Fabrice Barlesi; Matthew G Krebs; Alice T Shaw; Filippo de Braud; Christian Rolfo; Myung-Ju Ahn; Jürgen Wolf; Takashi Seto; Byoung Chul Cho; Manish R Patel; Chao-Hua Chiu; Thomas John; Koichi Goto; Christos S Karapetis; Hendrick-Tobias Arkenau; Sang-We Kim; Yuichiro Ohe; Yu-Chung Li; Young K Chae; Christine H Chung; Gregory A Otterson; Haruyasu Murakami; Chia-Chi Lin; Daniel S W Tan; Hans Prenen; Todd Riehl; Edna Chow-Maneval; Brian Simmons; Na Cui; Ann Johnson; Susan Eng; Timothy R Wilson; Robert C Doebele Journal: Lancet Oncol Date: 2019-12-11 Impact factor: 41.316